In summary, PDUFA stays a cornerstone of the current FDA drug review procedure, particularly due to the fact Congress has demonstrated no interest in growing immediate appropriations to the company. The service fees generated by PDUFA have permitted the FDA to rent additional staff members, drastically strengthen evaluation moments for medicine and